Incidence and prognostic factors in patents (Pts) with mutant braf (mbraf) metastatic colorectal cancer (MCRC) in Russia

Incidence and prognostic factors in patents (Pts) with mutant braf (mbraf) metastatic colorectal cancer (MCRC) in Russia Full article

Journal

Meditsinskiy Sovet
ISSN: 2079-701X

Output data

Year: 2021, Number: 4S, Pages: 52-63 Pages count : 12 DOI: 10.21518/2079-701X-2021-4S-52-63

Tags

Colorectal cancer; Epidemiology; Free progression survival; MBRAF; Overall survival; Prognosis

Authors

Fedyanin M.Yu. ^1,2,3 , Ehlsnukaeva K.K.-M. ¹ , Demidova I.A. ¹ , Stroyakovskiy D.L. ⁴ , Shelygin Y.A. ⁵ , Tsukanov A.S. ⁵ , Panina M.V. ⁵ , Shubin V.P. ⁵ , Moiseenko F.V. ^6,7 , Karpenko E.Yu. ⁸ , Bolotina L.V. ⁸ , Kudryavtseva A.V. ^8,9 , Filipenko M.L. ¹⁰ , Oskorbin I.P. ¹⁰ , Vladimirova L.Yu. ¹¹ , Timoshkina N.N. ¹¹ , Kit O.I. ¹¹ , Stroganova A.M. ¹ , Dranko S.L. ¹ , Senderovich A.I. ¹ , Tryakin A.A. ^1,12 , Tjulandin S.A. ¹

Affiliations

1	Blokhin National Medical Research Center of Oncology, 24, Kashirskoye Shosse, Moscow, 115478, Russian Federation
2	Peoples’ Friendship, University of Russia, 21/3, Miklukho-Maklai St, Moscow, 117198, Russian Federation
3	City Clinical Hospital No, 40
4	Moscow City Oncology Hospital No. 62, 27, Bldg. 1–26, Istra Township, Stepanovskoe P/O, Krasnogorsky District, Moscow Region, 143423, Russian Federation
5	Ryzhikh State Scientific Center of Coloproctology, 2, Salyam Adil St, Moscow, 123423, Russian Federation
6	St Petersburg Clinical Research and Practical Center of Specialized Types of Medical Care (Oncologic), 68, Leningradskaya St., Pesochnyy Settlement, St Petersburg, 197758, Russian Federation
7	North-Western State Medical University named after I.I. Mechnikov, 41, Kirochnaya St, St Petersburg, 191015, Russian Federation
8	Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Center, 3, 2nd Botkinskiy Proezd, Moscow, 125834, Russian Federation
9	Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 32, Vavilov St, Moscow, 119334, Russian Federation
10	Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 8, Lavrentiev Ave, Novosibirsk, 630090, Russian Federation
11	National Medical Research Centre for Oncology, 63, 14 liniya St., Rostov-on-Don344037, Russian Federation
12	Bashkir State Medical University, 47, Zaki Validi St, Ufa, 450008, Russian Federation

Introduction. mBRAF mCRC has the aggressive phenotype. The incidence of such mutation in Europe and the USA is around 8–14%, in Asian countries – 4–8%. The purpose of this population-based study was to determine the incidence and identifying prognostic factors in pts with mBRAF mCRC in Russia. Materials and methods. A multicenter retrospective analysis of clinical data and treatment results of pts with mBRAF mCRC was performed. The main method for determining mutations was a PCR. The main efficacy endpoint was progression free survival (PFS) at the 1 st line. Multivariate analysis was performed using Cox regression model. Results and discussion. 437 out of 8648 pts (5.17%) with a known mutational status had mBRAF (V600). Clinical data were collected from 131/437 (30%): the right-sided primary tumor – in 58,6%, left-sided – in 19%, rectum – in 21,4%. ORR in pts with mBRAF was 31%, median PFS was 6 months. We didn’t revealed any differences between FOLFOXIRI and doublets (XELOX/ FOLFOX or XELIRI/FOLFIRI) in terms of PFS (HR 0.9, 95% CI 0.49–1.52, р = 0.6) and OS (HR 1.5, 95% CI 0.61–4.1, р = 0.35) in pts with mBRAF. Conclusions. The incidence of mBRAF gene in the population of pts with mCRC in the Russia is low and we found a high incidence of localization of the primary tumor in the rectum. We didn’t reveal any differences between the usual duplets and standard regimen for such mutation-FOLFOXIRI in term of 1 st line PFS. © 2021, Remedium Group Ltd. All rights reserved.

Fedyanin M.Y. , Ehlsnukaeva K.K.-M. , Demidova I.A. , Stroyakovskiy D.L. , Shelygin Y.A. , Tsukanov A.S. , Panina M.V. , Shubin V.P. , Moiseenko F.V. , Karpenko E.Y. , Bolotina L.V. , Kudryavtseva A.V. , Filipenko M.L. , Oskorbin I.P. , Vladimirova L.Y. , Timoshkina N.N. , Kit O.I. , Stroganova A.M. , Dranko S.L. , Senderovich A.I. , Tryakin A.A. , Tjulandin S.A.
Incidence and prognostic factors in patents (Pts) with mutant braf (mbraf) metastatic colorectal cancer (MCRC) in Russia
Meditsinskiy Sovet. 2021. N4S. P.52-63. DOI: 10.21518/2079-701X-2021-4S-52-63 Scopus OpenAlex

Федянин М.Ю. , Эльснукаева Х.М. , Демидова И.А. , Строяковский Д.Л. , Шелыгин Ю.А. , Цуканов А.С. , Панина М.В. , Шубин В.П. , Моисеенко Ф.В. , Карпенко Е.Ю. , Болотина Л.В. , Кудрявцева А.В. , Филипенко М.Л. , Оскорбин И.П. , Владимирова Л.Ю. , Тимошкина Н.Н. , Кит О.И. , Строганова А.М. , Дранко С.Л. , Сендерович А.И. , Трякин А.А. , Тюляндин С.А.
Колоректальный рак с мутацией в гене BRAF в Российской Федерации: эпидемиология и клинические особенности. результаты многоцентрового исследования
Медицинский совет. 2021. Т.4. С.52-63. РИНЦ

Scopus:	2-s2.0-85118970976
OpenAlex:	W4361868929

DB	Citing
Scopus	1
OpenAlex	12